Julie A. Johnson

From 2015 to 2017, Johnson was a Clarivate Analytics Highly Cited Researcher in Pharmacology and Toxicology, indicating she was one of "the world's leading scholars in the sciences and social sciences." In 2018, she was recognized as an influencer across several fields during the last decade beyond the pharmacology and toxicology category. She also leads one of the funded groups in the NIH’s genomic medicine implementation network, called IGNITE, for which she was inaugural chair of its steering committee.

As a result of her academic achievements and research, Johnson was elected a Member of the National Academy of Medicine in October 2014. She is also an elected fellow of the American College of Clinical Pharmacy, the American Heart Association and the American College of Clinical Pharmacology. Johnson has served as the principal investigator and the director of the UF Health Precision Medicine Program studying genetic relations to medicine. In March 2015, she was elected president-elect of the American Society for Clinical Pharmacology and Therapeutics and served on its executive committee.

In 2010, Johnson led the International Warfarin Pharmacogenetics Consortium which aimed at developing a way to use genetic information from patients to help doctors better determine optimal warfarin doses. In 2013, Johnson led a research team which found that a genetic variation in African Americans directly affected their responses to the drug Warfarin. She analyzed health information and DNA samples from over 500 African-American adults on stable doses of warfarin to identify additional genetic factors. Her team concluded that African American adults who carry one or two copies of polymorphism need a dose reduction of roughly 7-9 mg less per week than other patients. During the same year, Johnson became the first woman to hold the title of Dean of the University of Florida College of Pharmacy and the seventh dean overall.

Johnson joined the faculty at the University of Florida College of Pharmacy in 1998 and was shortly thereafter appointed professor of pharmacy and medicine in cardiology. Her research focuses on the relationship between genetics and drug response, with the aim of assisting doctors in properly prescribing medications. She has been continuously funded by the National Institutes of Health or the American Heart Association since 1990. Her research has focused on the pharmacogenetics and clinical pharmacology of warfarin and medications used to treat high blood pressure, particularly beta-adrenergic receptor blockers and thiazide diuretics. More recently her research has extended to focus on the clinical implementation and clinical outcomes associated with using genetic information to guide drug therapy in cardiovascular disease, pain management and other diseases. In 2004, she was appointed the V. Ravi Chandran, Ph.D. Professor in Pharmaceutical Sciences and named to the editorial staff of the journal Clinical Pharmacology & Therapeutics.

Julie Ann Johnson (born 1962) is an American clinical pharmacist and translational scientist. She is the past dean (2013-2022) and a distinguished professor in the University of Florida College of Pharmacy and a Member of the National Academy of Medicine. For four consecutive years, she was a Clarivate Analytics Highly Cited Researcher in Pharmacology and Toxicology, indicating she was one of the "world's leading scholars in the sciences and social sciences in the preceding decade."